Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16718978 | 1.00 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL7848293 | 0.84 | OPRL1 (0.61) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL7842322 | 0.77 | FNTA (0.49) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL7839252 | 0.76 | FNTA (0.54) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL16731881 | 0.73 | FNTA (0.42) | TDP1 | |
| SCHEMBL16716813 | 0.73 | FNTA (0.39) | — | |
| SCHEMBL21634308 | 0.71 | OPRL1 (0.78) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL18135146 | 0.71 | FNTA (0.41) | TDP1 | |
| SCHEMBL9912156 | 0.71 | OPRL1 (0.74) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL16731917 | 0.71 | FNTA (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | claimed |
| EP-3068390-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | Merck Sharp & Dohme Corp. (US) | 2016-09-21 | — | — | EP | claimed |
| WO-2015073310-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | claimed |
| EP-3587411-B1 | 1-(ALPHA-METHYLBENZYL)-5-(PIPERIDINOMETHYL)IMIDAZOLE DERIVATIVES AND USES THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10745377-B2 | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use | MERCK SHARP & DOHME CORP. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745377-B2 | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use | MERCK SHARP & DOHME CORP. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015073310-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015070367-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745377-B2 | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use | CYP3A5, CYP3A43, CYP3A4 | OPRL1 3000/4885OPRM1 2138/4885OPRD1 1795/4885 |
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | CYP3A5, CYP3A43, CYP3A7 | OPRL1 3021/4885OPRM1 2530/4885OPRD1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.